Publicacións nas que colabora con Fernando Bandrés Moya (11)

2019

  1. Muscle Fitness Cut Points for Early Assessment of Cardiovascular Risk in Children and Adolescents

    Journal of Pediatrics, Vol. 206, pp. 134-141.e3

2017

  1. Cardiorespiratory Fitness Cutoff Points for Early Detection of Present and Future Cardiovascular Risk in Children: A 2-Year Follow-up Study

    Mayo Clinic Proceedings, Vol. 92, Núm. 12, pp. 1753-1762

  2. Convergent validation of a questionnaire to assess the mode and frequency of commuting to and from school

    Scandinavian Journal of Public Health, Vol. 45, Núm. 6, pp. 612-620

2016

  1. Inflammatory biomarkers and academic performance in youth. The UP & DOWN Study

    Brain, Behavior, and Immunity, Vol. 54, pp. 122-127

  2. Perceived environment in relation to objective and self-reported physical activity in Spanish youth. The UP&DOWN study

    Journal of Sports Sciences, Vol. 34, Núm. 15, pp. 1423-1429

2015

  1. Objectively measured and self-reported leisure-time sedentary behavior and academic performance in youth: The UP&DOWN Study

    Preventive Medicine, Vol. 77, pp. 106-111

2014

  1. Follow-up in healthy schoolchildren and in adolescents with DOWN syndrome: Psycho-environmental and genetic determinants of physical activity and its impact on fitness, cardiovascular diseases, inflammatory biomarkers and mental health; The UP&DOWN Study

    BMC Public Health, Vol. 14, Núm. 1

  2. Objective assessment of sedentary time and physical activity throughout the week in adolescents with Down syndrome: The UP&DOWN study

    Research in Developmental Disabilities, Vol. 35, Núm. 2, pp. 482-489

2010

  1. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants

    PLoS ONE, Vol. 5, Núm. 6

  2. CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): No effect of geographical isolation

    Annals of Human Biology, Vol. 37, Núm. 2, pp. 267-273

2009

  1. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORCI c.-l 639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 591-593